Hologic Inc. shares slid 2.7 percent today to $15.75 on a Canaccord Adams analyst’s downgrade, just a day after the Bedford, Mass.-based women’s health products maker posted a big Food & Drug Administration win, The Associated Press reported.
Canaccord Adams analyst Matthew Scalo downgraded shares to “hold” from “buy” but reaffirmed a $16 target price, according to the news service.
“We can debate how much of the S&P 500 growth is stimulus-related, but without significant outperformance from one of Hologic’s recent FDA-approved devices, we cannot argue that Hologic’s growth profile deserves a valuation multiple at or above the S&P 500,” Scalo wrote in a note to investors.
Hologic said yesterday that the FDA granted 510(k) approval for its MammoSite ML system, saying it plans to bring the device to market during the first quarter of fiscal 2010, which begins in October.
“While last night’s announcement of FDA clearance of a multi-lumen radiation catheter is a positive, we see this product as necessary to retain, if not regain, market share in this segment,” Scalo wrote, adding that the new device should add about $5 million to Hologic’s FY2010 revenue. But slumping hospital spending on large capital equipment could inhibit profit growth, he said.